Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$36.83 USD
-1.53 (-3.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.80 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
LBPH 36.83 -1.53(-3.99%)
Will LBPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LBPH
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
LBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Other News for LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Bexicaserin Shows Promise in Epilepsy Treatment, Justifying Buy Rating for Longboard Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Longboard Pharmaceuticals (LBPH) and Viridian Therapeutics (VRDN)
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Longboard Pharmaceuticals (LBPH) and R1 RCM (RCM)
Longboard Pharmaceuticals Advances with Promising Seizure Treatment Study